Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial.
Tepper SJ, Dodick DW, Lanteri-Minet M, Dolezil D, Gil-Gouveia R, Lucas C, Piasecka-Stryczynska K, Szabó G, Mikol DD, Chehrenama M, Chou DE, Yang Y, Paiva da Silva Lima G. Tepper SJ, et al. Among authors: piasecka stryczynska k. JAMA Neurol. 2024 Sep 16;81(11):1140-9. doi: 10.1001/jamaneurol.2024.3043. Online ahead of print. JAMA Neurol. 2024. PMID: 39283627 Free PMC article.
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS. Montalban X, et al. Among authors: piasecka stryczynska k. Mult Scler. 2024 Apr;30(4-5):558-570. doi: 10.1177/13524585241234783. Epub 2024 Mar 4. Mult Scler. 2024. PMID: 38436271 Free PMC article. Clinical Trial.
Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Stępień A, Pogoda-Wesołowska A, Tokarz-Kupczyk E, Słowik A, Puz P, Adamczyk-Sowa M, Kurkowska-Jastrzębska I, Kułakowska A, Chorąży M, Piasecka-Stryczyńska K, Jamróz-Wiśniewska A, Bartosik-Psujek H, Rejdak K. Stępień A, et al. Among authors: piasecka stryczynska k. Neurol Neurochir Pol. 2023;57(4):371-378. doi: 10.5603/PJNNS.a2023.0050. Epub 2023 Jul 25. Neurol Neurochir Pol. 2023. PMID: 37490356 Free article.
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group. Montalban X, et al. Among authors: piasecka stryczynska k. N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10. N Engl J Med. 2019. PMID: 31075187 Clinical Trial.
"Positive Regulation of RNA Metabolic Process" Ontology Group Highly Regulated in Porcine Oocytes Matured In Vitro: A Microarray Approach.
Celichowski P, Nawrocki MJ, Dyszkiewicz-Konwińska M, Jankowski M, Budna J, Bryja A, Kranc W, Borys S, Knap S, Ciesiółka S, Jeseta M, Piasecka-Stryczyńska K, Khozmi R, Bukowska D, Antosik P, Brüssow KP, Bruska M, Nowicki M, Zabel M, Kempisty B. Celichowski P, et al. Among authors: piasecka stryczynska k. Biomed Res Int. 2018 Jan 10;2018:2863068. doi: 10.1155/2018/2863068. eCollection 2018. Biomed Res Int. 2018. PMID: 29546053 Free PMC article.